Found 12447 matches for
The 5-year programme award will support research on the DNA repair mechanisms that protect cancer cells from therapy, informing the development of future treatments.
If you are a CI / PI of an upcoming clinical trial, with accompanying laboratory studies, you may want to consider using a new state-of-the-art ISO-17025 accredited, GCP Therapy Acceleration Laboratory (TAL) based in the Medical Research Council Weatherall Institute of Molecular Medicine (WIMM) to do the laboratory studies. The TAL will analyse human samples from national and international Phase I to Phase III trials of novel targeted therapies that maximise patient impact, transform understanding of disease biology, dissect mechanisms of action of therapies and mechanisms of response. It will be open to all PIs in Oxford from early 2022. It will offer a wide selection of next generation sequencing genetic and deep phenotyping assays on cells and tissues, work closely with the WIMM single cell and imaging facilities and support long term bio-banking of nucleic acids and viable cells. The laboratory will work with PIs to add value to a clinical trial, offering assays that allow patient selection at the start of a trial, patient stratification into different therapy arms during the trial, validation of secondary endpoints for more rapid trials and exploratory endpoints. Careful analysis can also provide mechanistic data on how therapies work in patients, providing confidence to regulators. If you would like to have an initial informal discussion about how TAL might be able to contribute to your trial, please contact Professor Paresh Vyas: firstname.lastname@example.org